SCHEMBL1359896

SCHEMBL1359896

N#Cc1ccc2ccc(N)cc2n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.54
KMT2A Q03164 2/20 0.54
MEN1 O00255 1/20 0.54
F2 P00734 1/20 0.54
CHRM2 P08172 1/20 0.54
HTR1A P08908 1/20 0.54
ADRA2A P08913 1/20 0.54
ADORA3 P0DMS8 1/20 0.54
MAOA P21397 1/20 0.54
DRD1 P21728 1/20 0.54
ACHE P22303 1/20 0.54
PTGS1 P23219 1/20 0.54
SLC6A2 P23975 1/20 0.54
SLC6A4 P31645 1/20 0.54
OPRM1 P35372 1/20 0.54
DRD3 P35462 1/20 0.54
KDR P35968 1/20 0.54
HTT P42858 1/20 0.54
SLC6A3 Q01959 1/20 0.54
KCNH2 Q12809 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL906662 0.86 NQO1 (0.59) LMNAKMT2AMEN1F2CHRM2
SCHEMBL756229 0.76 CYP1A2 (0.55) KMT2AMEN1NQO1KDM4EALDH1A1
SCHEMBL11038799 0.76 NQO1 (0.47) KMT2AMEN1NQO1KDM4EALDH1A1
SCHEMBL22511767 0.76 NQO1 (0.44) NQO1SOS2
Hydrazine SCHEMBL28226443 0.73 GRM5 (0.50) KMT2AMEN1ACHEKCNH2NQO1
SCHEMBL29359679 0.72 GRM5 (0.53) ACHEKCNH2NQO1KDM4EALDH1A1
SCHEMBL27416745 0.72 GRM5 (0.53) ACHEKCNH2NQO1KDM4EALDH1A1
SCHEMBL75226 0.72 GRM5 (0.53) ACHEKCNH2NQO1KDM4EALDH1A1
SCHEMBL14629283 0.72 NQO1 (0.56) KMT2AMEN1ACHEKCNH2NQO1
SCHEMBL5020257 0.72 NQO1 (0.51) KMT2AMEN1NQO1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067582-B2 Fused heterocyclic compounds useful as modulators of nuclear hormone receptor function BRISTOL-MYERS SQUIBB COMPANY (US) 2011-11-29 US disclosed
US-20100331324-A1 FUSED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION BRISTOL-MYERS SQIOBB COMPANY 2010-12-30 US disclosed
EP-2170899-A1 FUSED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION Bristol-Myers Squibb Company (US) 2010-04-07 EP disclosed
WO-2009003077-A1 FUSED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION BRISTOL-MYERS SQUIBB COMPANY (US) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331324-A1 FUSED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION NR5A1, AR, ESRRA LMNA 4108/4885KMT2A 3020/4885MEN1 1153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.